ישראל - עברית - Ministry of Health

truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

ישראל - עברית - Ministry of Health

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - hepatitis b immunoglobulin - תמיסה להזרקה - hepatitis b immunoglobulin 220 iu/ml - hepatitis b immunoglobulin - hepatitis b immunoglobulin - for post-exposure prophylaxis such as: - acute exposure to blood containing hbsag, - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag positive persons, - household exposure to persons with acute hbv infections.